When Botta & Maestroni used a tumour antigen-specific dendritic cell vaccine strategy to target a thymoma cell line expressing the ovalbumin antigen (EL-4 transfected with OVA), they found that an intradermal injection of the β2-AR agonist salbutamol impaired the efficacy of the anti-tumour dendritic cell vaccine treatment (Botta 2008). This evidence concerns the gene ADRB2 and neoplasm.